TrialInvestigational new drugs2013

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Christopher W Ryan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.